eDSP — NDA/BLA submission
H2 2026
Assuming positive study results, the company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.Source filing
QNCX biotech catalysts & pipeline
QUINCE THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
LAM-001 — Clinical data readout
1Q 2027
TRIAL FULLY ENROLLED, DATA ANTICIPATED 1Q 2027Source filing
LAM-001 — Topline data
Q1 2028
Phase 2b trial in PH-ILD to initiate in mid-2026, with topline data anticipated in the first quarter of 2028Source filing
LAM-001 — Clinical data readout
Q4 2028
The Company plans to initiate a Phase 2 study in SAPH in 4Q26, with data anticipated in the fourth quarter of 2028.Source filing